New Bladder-Saving cancer combo enters human testing
NCT ID NCT05833867
Summary
This study is testing the safety of combining a new, targeted cancer drug called sacituzumab govitecan with precise, image-guided radiation therapy. The goal is to control muscle-invasive bladder cancer in patients who cannot or choose not to have their bladder surgically removed. Researchers will enroll about 20 participants to see if this combination is safe and feasible as a way to preserve the bladder.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44195, United States
Contact
Conditions
Explore the condition pages connected to this study.